यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - Множествена миелома - Антинеопластични средства - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Антинеопластични средства - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

archie samuel s.r.o. - клопидогрел - peripheral vascular diseases; stroke; myocardial infarction - Антитромботични агенти - Клопидогрел е показан за възрастни за профилактика на атеротромботических събития:пациенти, страдащи инфарктом инфаркт (от няколко дни до по-малко от 35 дни), исхемичен инсулт (от 7 дни до по-малко от 6 месеца) или установена заболяване на периферните артерии. За повече информация, моля, вижте раздел 5.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

roche registration limited - emicizumab - Хемофилия А - Антихеморагични - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra могат да бъдат използвани във всички възрастови групи.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - псориазис - Имуносупресори - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - Лимфом, фоликуларен - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

eli lilly nederland b.v. - терипаратид - osteoporosis; osteoporosis, postmenopausal - Калциева хомеостаза - Лечение на остеопороза при жени в постменопауза и при мъже с повишен риск от фрактури. При жени в постменопауза е доказано значително намаляване на честотата на фрактури на гръбначни и невертебрални фрактури, но не и на фрактури на бедрената кост. Лечение на остеопороза, свързан с постоянна и системна терапия глюкокортикоидами, при жените и мъжете при повишен риск от фрактури.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil хидрохлорид - Колоректални неоплазми - Антинеопластични средства - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

astrazeneca ab - фулвестрант - Неоплазми на гърдата - Ендокринната терапия, антиэстрогены - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. В пре - или менопауза, в комбинираното лечение с palbociclib трябва да се комбинира с lhrh лутеинизиращ хормон освобождаващ хормон (lhrh) агонист.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

sanofi b.v. - тиротропин алфа - Тироидни неоплазми - Хормони на предния дял на хипофизата и аналози, хипофизата и гипоталамические хормони и аналози - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.